A novel regimen of combination transdermal estrogen and intermittent vaginally administered progesterone for relief of menopausal symptoms

Gynecological Endocrinology

Volumn 26, Issue 12, 2010, Pages 902-908

  Kroft, Jamie ^a   Klostermann, Natalie R ^a   Moody, Joel R K ^a   Taerk, Evan ^a   Wolfman, Wendy ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

estrogen plus progestogen therapy; Progesterone; vaginal administration

Indexed keywords

ESTRADIOL; ESTROGEN; PROGESTERONE;

ADULT; AGED; AMENORRHEA; ARTICLE; BLEEDING; BREAST TENDERNESS; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM BIOPSY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; AGED; ENDOMETRIUM; ESTRADIOL; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 78149455429     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.487602     Document Type: Article

References (36)

1. Ziel HK, Finkle WD. Increased risk ofendometrial carcinoma amongst users ofconjugated estrogens. N Eng J Med 1975; 293:1167-1170.
2. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcino-ma. N Eng J Med 1977;293:1164-1167.
3. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R. Endometrial cancer and estrogen use. Report of a large case-control study. N Eng J Med 1979; 300:9-13. (Pubitemid 9095976)
4. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. ObstetGynecol 1995;85:304-313.
5. Pickar J, Tien Yeh I, Wheeler J, Cunnane M, Speroff L. Endometrial effects of lower doses of conjugatedequine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31. (Pubitemid 32600955)
6. Whitehead MI, Queen J, Beard RN, Minardi J, Campbell S. The effects of cyclical estrogen therapy and sequential estrogen therapy on the endometrium of postmenopausal women. Acta Obst Gynae Scand Supp 1977;65:91-101. (Pubitemid 8198211)
7. Cust MP, Gangar KF, Hillard TC, Whitehead MI. A risk benefit assessment of estrogen therapy in post menopausal women. Drug Safety 1990;5:345-358.
8. Udoff L, Langenberg P, Adashi E. Combined continuous hormone replacement therapy: a clinical review. Obstet Gynecol 1995;86:306-316.
9. Corson S, Richart R, Caubel P, Lim P. Effect of a unique constant estrogen, pulsed progestin hormone replacement therapy containing 17B estradiol and norgestimate on endometrial histology. Int J Fertil 1999;44:279-85. (Pubitemid 30043394)
10. Nahoul K, Dehennin L, Scholler R. Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J Steroid Biochem 1987;26:241-249. (Pubitemid 17040129)
11. Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 2000;73:516-521. (Pubitemid 30109647)
12. Arafat ES, Hargrove JT, Maxson WS, Desiderio DM, Wentz AC, Andersen RN. Sedative and hypnotic effects oforal administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol 1988;159: 1203-1209
13. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273: 199-208.
14. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
15. Anderson GL, Limacher M, AssafAR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712. (Pubitemid 38489892)
16. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;363:419-427. (Pubitemid 36999703)
17. Olsson H, Ingvar C, Bladström A. Hormone replacement therapy containing progestins and given continuously espe-cially increases breast cancer risk in southern Sweden. Cancer 2003;97:1387-1392. (Pubitemid 36297767)
18. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111. (Pubitemid 350179584)
19. Odlind V. New delivery systems for hormonal contraception. Acta Obstet Gynaecol Scand 1986;134:15-20. (Pubitemid 17190172)
20. Wood CE, Sitruk-Ware RL, Tsong Y, Register TC, Lees CJ, Cline JM. Effects of estradiol with oral or intravaginal progesterone on risk markers for breast cancer in a post-menopausal monkey model. Menopause 2007;14:639-647. (Pubitemid 47051956)
21. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Comparative effects of estrogen with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2006;101:125-134. (Pubitemid 46115419)
22. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62: 485-490. (Pubitemid 24273195)
23. Cicinelli E, Cignarelli M, Sabatelli S, Romano F, Schonauer LM, Padovano R, Einer-Jensen N. Plasma con-centrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to post-meopausal women. Fertil Steril 1998;69:471-473. (Pubitemid 28146558)
24. Cicinelli E, de Ziegler D, Bulletti C, Matteo GM, Schonauer LM, Galantino P. Direct transport ofprogesterone from vagina to uterus. Obstet Gynecol 2000;95:403-406. (Pubitemid 30100507)
25. de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in Menopause Crinone 4% in cyclical and constantcombined regimens. Hum Reprod 2000;15:149-158. (Pubitemid 30410136)
26. Cicinelli E, de Ziegler D, Galantino P, Pinto V, Barba B, Morgese S, Schonauer S. Twice weekly transdermal estradiol and vaginal progesterone as continous combined hormone replacement therapy in postmenopausal women a 1-year prospective study. Am J Obstet Gynecol 2002;187:556-560.
27. Cicinelli E, de Ziegler D, Alfonso R, Nicoletti R, Bellavia M, Colafiglio G. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005;83:1859-1863. (Pubitemid 40824830)
28. Modena MG, Sismondi P, Mueck AO, Kuttenn F, de Lignieres B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR. New evidence regarding hormone replacement therapies is urgently required: transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52:1-10 (Pubitemid 41242736)
29. Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmeno-pausal women. The postmenopausal estrogen/progestin inter-ventions (PEPI) Trial. JAMA 1996;275:370-375.
30. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabal JF, Barnabei VM, Merino MJ, Scully RE. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. N Engl J Med 1997;337:1792-1798. (Pubitemid 28006783)
31. Magos AL, Brincat M, Studd JWW, Wardle P, Schlesinger P, O'Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in post-menopausalwomen. ObstetGynecol 1985;65:496-499. (Pubitemid 15099146)
32. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medrox-yprogesterone acetate. Obstet Gynecol 1994;83:686-692. (Pubitemid 24153460)
33. Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 2002;100: 853-863.
34. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001;21:464-480.
35. Pessina MA, Richard F Jr, Goldstein I, Traish AM. Differential effects ofestradiol, progesterone, and testosterone on vaginal structural integrity. Endocrinology 2006;147: 61-69. (Pubitemid 43004263)
36. Henderson BD, Paganini-Hilll A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch InternMed 1991;151:75-78.